Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Zimlovisertib + tofacitinib was more effective than tofacitinib for the primary endpoint, whereas the efficacy of zimlovisertib + ritlecitinib did not achieve statistical significance versus tofacitinib. All treatments were well tolerated.
Authors
- Steven A. Gilbert (ORCID: https://orcid.org/0000-0003-1438-1847)
- Paweł Hrycaj (ORCID: https://orcid.org/0000-0003-1253-8062)
- Ravi Shankar Prasad Singh (ORCID: https://orcid.org/0000-0001-6298-8219)
- Elena Peeva
- Negin Shojaee
- Spencer I. Danto (ORCID: https://orcid.org/0000-0002-0587-5274)
- Irina Jashi
- Michael S. Vincent
- M.P. Salganik
- Jean S. Beebe
- Karen Page (ORCID: https://orcid.org/0000-0002-6139-642X)
- Anindita Banerjee (ORCID: https://orcid.org/0000-0003-2982-2940)
Institutions
- Pfizer (United States) (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1002/art.43184
- Citations
- 5
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 8.34
Funders
- Pfizer